CEP1612

CEP1612 is a dipeptidyl proteasome inhibitor with the IC50 of 60 nM. CEP1612 induces p21 (WAF1) and p27 (KIP1) expression and cell apoptosis. CEP1612 shows anticancer activity in vivo[1][2].

Product Specifications

CAS Number

[189036-01-9]

UNSPSC

12352005

Target

Apoptosis; Proteasome

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/cep1612.html

Smiles

O=C1C2=CC=CC=C2C(N1CCCCCCCCC(C3CCCC3)C(N[C@@H](CCCNC(NN(=O)=O)=N)C(N[C@H](C=O)CC(C)C)=O)=O)=O

Molecular Formula

C35H53N7O7

Molecular Weight

683.84

References & Citations

[1]Sun J, et al. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res. 2001;61 (4) :1280-1284. |[2]An B, et al. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 1998;5 (12) :1062-1075.